or Try an Advanced Search...

    Technical Analysis for GRCE - Grace Therapeutics, Inc.

    Grade Last Price % Change Price Change
    B 3.28 4.13% 0.13
    GRCE closed up 4.13 percent on Wednesday, November 20, 2024, on 1.65 times normal volume. It was able to find support at its 50 day moving average.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Up Up
    Historical GRCE trend table...
    Date Alert Name Type % Chg
    50 DMA Support Bullish 0.00%
    Crossed Above 20 DMA Bullish 0.00%
    MACD Bullish Signal Line Cross Bullish 0.00%
    Expansion Pivot Buy Setup Bullish Swing Setup 0.00%
    Pocket Pivot Bullish Swing Setup 0.00%
    Outside Day Range Expansion 0.00%
    Upper Bollinger Band Touch Strength 0.00%
    Gapped Down Weakness 0.00%
    20 DMA Resistance Bearish 4.13%
    50 DMA Support Bullish 4.13%
    Older End-of-Day Signals for GRCE ...

       Recent Intraday Alerts

    Alert Time
    Rose Above 20 DMA about 17 hours ago
    10 DMA Support about 17 hours ago
    50 DMA Support about 17 hours ago
    Rose Above Previous Day's High about 17 hours ago
    Rose Above Upper Bollinger Band about 17 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    GRCE Chart by TradingView
    Basic chart:

    Profile

    Grace Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. It focuses on the research of prescription drugs using omega-3, fatty acids derived from krill oil. The company was founded by Henri Harland and Pierre Lemieux on February 1, 2002, and is headquartered in Princeton, NJ.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Biopharmaceutical Pharmacy Medication Cardiovascular Disease Pharmaceutical Applications

    Is GRCE a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 18 GRCE: FY:25 Second Quarter Results
    Nov 15 Grace Therapeutics And 2 Other US Penny Stocks To Watch
    Nov 13 Grace Therapeutics GAAP EPS of -$0.30 beats by $0.06
    Nov 13 Grace Therapeutics Announces Second Fiscal Quarter 2025 Financial Results, Provides Business Update
    Nov 4 GRCE: Initiating Coverage – From Confusion to Infusion
    Oct 29 OTC Markets Hosts Virtual Investor Presentation with Prashant Kohli, CEO of Grace Therapeutics (Acasti Pharma), with John Vandermosten, Senior Analyst at Zacks SCR
    Oct 25 Acasti Pharma changes name to Grace Therapeutics
    Oct 25 Acasti Announces Corporate Name Change to Grace Therapeutics, Inc.
    Sep 25 Acasti Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104
    Sep 20 Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
    See more GRCE news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 3.6
    52 Week Low 1.98
    Average Volume 36,976
    200-Day Moving Average 2.97
    50-Day Moving Average 3.05
    20-Day Moving Average 3.18
    10-Day Moving Average 3.13
    Average True Range 0.25
    RSI (14) 54.95
    ADX 22.72
    +DI 23.22
    -DI 8.88
    Chandelier Exit (Long, 3 ATRs) 2.84
    Chandelier Exit (Short, 3 ATRs) 3.64
    Upper Bollinger Bands 3.48
    Lower Bollinger Band 2.88
    Percent B (%b) 0.67
    BandWidth 18.82
    MACD Line 0.02
    MACD Signal Line 0.02
    MACD Histogram 0.0012
    Fundamentals Value
    Market Cap 30.83 Million
    Num Shares 9.4 Million
    EPS -5.65
    Price-to-Earnings (P/E) Ratio -0.58
    Price-to-Sales 208.39
    Price-to-Book 0.35
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 4.00
    Resistance 3 (R3) 3.99 3.74 3.88
    Resistance 2 (R2) 3.74 3.56 3.75 3.84
    Resistance 1 (R1) 3.51 3.44 3.63 3.52 3.80
    Pivot Point 3.26 3.26 3.32 3.27 3.26
    Support 1 (S1) 3.03 3.08 3.15 3.04 2.76
    Support 2 (S2) 2.78 2.96 2.79 2.72
    Support 3 (S3) 2.55 2.78 2.68
    Support 4 (S4) 2.56